BR112016029916A2 - inibidores mnk e métodos correlatos - Google Patents

inibidores mnk e métodos correlatos

Info

Publication number
BR112016029916A2
BR112016029916A2 BR112016029916A BR112016029916A BR112016029916A2 BR 112016029916 A2 BR112016029916 A2 BR 112016029916A2 BR 112016029916 A BR112016029916 A BR 112016029916A BR 112016029916 A BR112016029916 A BR 112016029916A BR 112016029916 A2 BR112016029916 A2 BR 112016029916A2
Authority
BR
Brazil
Prior art keywords
formula
compounds
related methods
pharmaceutically acceptable
mnk inhibitors
Prior art date
Application number
BR112016029916A
Other languages
English (en)
Other versions
BR112016029916B1 (pt
Inventor
Xin Xiang Alan
Thomas ERNST Justin
A Sprengeler Paul
H Reich Siegfried
E Webber Stephen
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of BR112016029916A2 publication Critical patent/BR112016029916A2/pt
Publication of BR112016029916B1 publication Critical patent/BR112016029916B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

a presente invenção refere-se a compostos de acordo com a fórmula (i): ou um estereoisómero, tautómero ou um sal farmaceuticamente aceitável, em que r1, r2, r3, r4a, r4b, r5, r6, r7, r8, w1, w2, y e n são como aqui definidos. também são descritas composições farmaceuticamente aceitáveis de compostos da fórmula (i) bem como métodos para utilizar os compostos da fórmula (i) e as composições farmaceuticamente aceitáveis de compostos da fórmula (i) como inibidores de mnk, assim como agentes terapêuticos para o tratamento de doenças tais como câncer.
BR112016029916-7A 2014-06-25 2015-06-24 Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, composição farmacêutica e processo para preparar composto ou sal farmaceuticamente aceitável do mesmo BR112016029916B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017112P 2014-06-25 2014-06-25
US62/017,112 2014-06-25
PCT/US2015/037416 WO2015200481A1 (en) 2014-06-25 2015-06-24 Mnk inhibitors and methods related thereto

Publications (2)

Publication Number Publication Date
BR112016029916A2 true BR112016029916A2 (pt) 2017-08-22
BR112016029916B1 BR112016029916B1 (pt) 2023-12-12

Family

ID=53724447

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029916-7A BR112016029916B1 (pt) 2014-06-25 2015-06-24 Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, composição farmacêutica e processo para preparar composto ou sal farmaceuticamente aceitável do mesmo

Country Status (24)

Country Link
US (6) US9382248B2 (pt)
EP (2) EP3160966B1 (pt)
JP (2) JP6615797B2 (pt)
KR (1) KR102460389B1 (pt)
CN (2) CN106795162B (pt)
AU (1) AU2015279984B2 (pt)
BR (1) BR112016029916B1 (pt)
CA (1) CA2953365C (pt)
CL (1) CL2016003293A1 (pt)
CO (1) CO2017000399A2 (pt)
DK (2) DK3160966T3 (pt)
EA (1) EA033920B1 (pt)
ES (1) ES2728201T3 (pt)
FI (1) FI3521289T3 (pt)
IL (1) IL249557B (pt)
MX (1) MX2016017030A (pt)
MY (1) MY189363A (pt)
NZ (1) NZ728007A (pt)
PE (1) PE20170321A1 (pt)
PH (1) PH12016502504A1 (pt)
SG (2) SG11201610511YA (pt)
TW (1) TWI713455B (pt)
WO (1) WO2015200481A1 (pt)
ZA (1) ZA201700241B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
EP3285809B1 (en) * 2015-04-20 2019-09-11 eFFECTOR Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
AU2016343687A1 (en) 2015-10-29 2018-06-07 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
EA034440B1 (ru) 2015-10-29 2020-02-07 Эффектор Терапьютикс, Инк. СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
US20170191136A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11629146B2 (en) 2016-11-28 2023-04-18 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity
EP3571206A1 (en) 2017-01-20 2019-11-27 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
TW201831479A (zh) * 2017-01-20 2018-09-01 德商拜耳製藥公司 經取代二氫咪唑并吡啶二酮
WO2018148745A1 (en) * 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
CA3053493A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
SG11202011879RA (en) 2018-05-30 2020-12-30 Praxis Prec Medicines Inc Ion channel modulators
JP2022505846A (ja) 2018-10-24 2022-01-14 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ阻害剤の結晶形態
WO2020108619A1 (zh) * 2018-11-30 2020-06-04 上海迪诺医药科技有限公司 Mnk抑制剂
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
EP3972593A4 (en) * 2019-05-23 2023-06-28 Board of Regents, The University of Texas System Inhibitor of mnk for the treatment of neuropathic pain
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
WO2021001743A1 (en) 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translation inhibitors and uses thereof
US11286268B1 (en) 2019-07-02 2022-03-29 Effector Therapeutics, Inc. EIF4E-inhibiting compounds and methods
WO2021016263A1 (en) * 2019-07-21 2021-01-28 University Of Virginia Patent Foundation Cysteine binding compositions and methods of use thereof
KR20220101686A (ko) * 2019-11-18 2022-07-19 점보 드러그 뱅크 컴퍼니 리미티드 Mnk 억제제로서의 피롤로트리아진 화합물
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
CN116194112A (zh) * 2020-06-30 2023-05-30 4E治疗公司 表现出mnk抑制作用的吡啶-1,5-二酮及其使用方法
US20240092799A1 (en) * 2020-08-20 2024-03-21 Hepagene Therapeutics (HK) Limited Mnk inhibitors
US11925642B2 (en) 2020-10-08 2024-03-12 Board Of Regents, The University Of Texas System Regulation of eIF4E activity for migraine therapy
KR20240004828A (ko) * 2021-05-08 2024-01-11 점보 드러그 뱅크 컴퍼니 리미티드 피롤로트리아진 화합물의 염 형태, 이의 결정형 및 이의 제조 방법
CA3225747A1 (en) * 2021-06-30 2023-01-05 4E Therapeutics, Inc. Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
IL310590A (en) * 2021-08-05 2024-04-01 4E Therapeutics Inc Methods of treating migraine with MNK inhibitors
CN114736205B (zh) * 2022-03-31 2023-03-03 武汉九州钰民医药科技有限公司 化合物Tomivosertib的制备方法
CN114671869B (zh) * 2022-03-31 2023-06-30 武汉九州钰民医药科技有限公司 化合物Tomivosertib的合成方法
CN114853756B (zh) * 2022-03-31 2023-03-28 武汉九州钰民医药科技有限公司 化合物Tomivosertib的制备工艺

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491144A (en) 1991-05-30 1996-02-13 Ciba-Geigy Corporation Substituted diaminophthalimides and analogues
US9357797B2 (en) * 1999-11-06 2016-06-07 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
DE60219788T2 (de) * 2001-06-05 2008-01-17 Lilly Icos Llc, Wilmington Tetrazyklische verbindungen als pde5-inhibitoren
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
JP2009509921A (ja) 2005-08-12 2009-03-12 アストラゼネカ アクチボラグ 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用
JP2009541268A (ja) * 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2727909A1 (en) 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
JP2009173629A (ja) 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
AU2009286734A1 (en) * 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
AU2011310532B2 (en) 2010-10-01 2016-01-14 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013043192A1 (en) 2011-09-23 2013-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders
PE20141404A1 (es) 2011-12-30 2014-10-28 Hanmi Pharm Ind Co Ltd Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
WO2013148748A1 (en) 2012-03-29 2013-10-03 Francis Xavier Tavares Lactam kinase inhibitors
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
EP2852593A1 (en) * 2012-05-21 2015-04-01 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2917185B1 (en) * 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
GB2508652A (en) 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
EP2958920A1 (en) 2013-02-20 2015-12-30 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
TW201605867A (zh) 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
BR112017013148A2 (pt) * 2014-12-19 2019-11-19 Bayer Pharma AG pirazolopiridinaminas como inibidores mknk1 e mknk2
AU2016343687A1 (en) 2015-10-29 2018-06-07 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
EA034440B1 (ru) 2015-10-29 2020-02-07 Эффектор Терапьютикс, Инк. СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2
GB201520500D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds

Also Published As

Publication number Publication date
AU2015279984A1 (en) 2017-01-19
NZ728007A (en) 2023-03-31
ES2728201T3 (es) 2019-10-22
US20180085368A1 (en) 2018-03-29
JP2017519782A (ja) 2017-07-20
EA201790078A1 (ru) 2017-05-31
KR102460389B1 (ko) 2022-10-27
IL249557B (en) 2021-10-31
DK3160966T3 (da) 2019-05-27
US20160317536A1 (en) 2016-11-03
JP6615797B2 (ja) 2019-12-04
EP3160966B1 (en) 2019-02-27
FI3521289T3 (fi) 2024-01-09
MX2016017030A (es) 2017-09-11
CO2017000399A2 (es) 2017-04-28
US9382248B2 (en) 2016-07-05
CA2953365A1 (en) 2015-12-30
CA2953365C (en) 2023-08-08
US9814718B2 (en) 2017-11-14
CN110183449A (zh) 2019-08-30
WO2015200481A1 (en) 2015-12-30
US20210338673A1 (en) 2021-11-04
PE20170321A1 (es) 2017-04-05
WO2015200481A8 (en) 2016-06-30
SG11201610511YA (en) 2017-01-27
SG10201811384TA (en) 2019-01-30
EP3160966A1 (en) 2017-05-03
TWI713455B (zh) 2020-12-21
AU2015279984B2 (en) 2019-12-05
PH12016502504A1 (en) 2017-04-10
MY189363A (en) 2022-02-07
ZA201700241B (en) 2022-05-25
CL2016003293A1 (es) 2017-09-08
KR20170023145A (ko) 2017-03-02
EA033920B1 (ru) 2019-12-10
CN106795162A (zh) 2017-05-31
BR112016029916B1 (pt) 2023-12-12
CN106795162B (zh) 2019-07-16
US20190209560A1 (en) 2019-07-11
CN110183449B (zh) 2022-08-19
JP2020063251A (ja) 2020-04-23
TW201613918A (en) 2016-04-16
EP3521289A1 (en) 2019-08-07
US20150376181A1 (en) 2015-12-31
EP3521289B1 (en) 2023-10-25
US20170266185A1 (en) 2017-09-21
IL249557A0 (en) 2017-02-28
DK3521289T3 (da) 2024-01-15
US9669031B2 (en) 2017-06-06
JP6979439B2 (ja) 2021-12-15

Similar Documents

Publication Publication Date Title
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112015021115A2 (pt) agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
EA201791576A1 (ru) Ингибитор jak
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
BR112015022462A2 (pt) inibidores de ido
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2015, OBSERVADAS AS CONDICOES LEGAIS